<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The earliest randomized, placebo-controlled, clinical trial was performed on 58 anxiety patients with non-psychotic origin [
 <xref rid="B367-molecules-24-01364" ref-type="bibr" class="xref">367</xref>]. 100 mg kava extract (WS1490, a pharmaceutical extract) or placebo preparation was administered to patients daily three times during four week period. Drug receiving group demonstrated a significant reduction in overall score of anxiety symptomatology assessed by Hamilton-Anxiety-Scale (HAMA) as main target variable just after one week of treatment. The difference between drug and placebo group increased in the course of study. No adverse experiences were observed during the treatment period of kava extract.
</p>
